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Lipid Binding Studies of
Blood Coagulation Factor VIII C1 and C2 Domains
Rachel Blazevic, Serena Wo and P. Clint Spiegel
Department of Chemistry, Western Washington University; Bellingham, WA

Introduction
The blood coagulation protein, factor VIII (FVIII), is a necessary cofactor for factor IXa in the mammalian blood coagulation cascade. To function as a cofactor, FVIII must bind to
the anionic phosphatidylserine head groups on the surface of platelets localized to the site of injury. Two domains, C1 and C2, are known to be involved in lipid binding,
however the working model for platelet binding needs to be bolstered by mutational studies to identify the necessary amino acid contacts. This work uses site directed
mutagenesis, metal affinity column chromatography, and enzyme-linked immunosorbent assays to directly compare the lipid binding affinities of single residue mutants of
isolated FVIII C1 domain and C2 domain relative to wild type C1 domain and C2 domain. Understanding the role of both residues may further the model of FVIII lipid binding
and provide the basis for development of more effective therapeutics.

Background
Blood Clotting Cascade
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In plasma, FVIII circulates complexed to
von Willebrand factor (vWf), which
protects it from rapid degradation. On
cleavage by thrombin, activated FVIII
dissociates from vWf, as a heterotrimer
(A1/A2/A3-C1-C2).
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Figure 1. FVIII Crystal Structure.1

• Hemophilia A is an X-linked bleeding disorder caused by inactive
coagulation protein, FVIII. This deficiency affects 1 in 5,000 males
worldwide and results in bleeding in joints, muscles, and soft tissues.

Figure 2. Blood
coagulation cascade.
Inactive FVIII circulates
in complex with VWF.
Following activation by
Fxa or thrombin, FVIII
dissociates from VWF
and binds active
platelet surfaces. Here
it serves as a cofactor
to serine protease FIXa
in the activation of FX.1

C1 & C2 Domain Mutations

• 75% of patients receive infusions of concentrated or recombinant
FVIII product. Recombinant FVIII is produced in eukaryotic cell lines
and is often genetically engineered to improve stability, secretion
levels, circulation half life, and decrease immunogenicity.
• Approximately 20% of hemophilia A patient develop anti-FVIII
pathogenic antibodies, known as inhibitors, that reduce treatment
efficacy.

R2320T R2320S R2159H R2163H

C1 Mutations:
R2159H
R2163H

Project Goal:
To assess the importance of the
four highlighted residues for C1
and C2 domain stability and
membrane binding capability.

C2 Mutations:
R2215A
R2320S
R2320T

These residues were chosen because of
their possible interactions with the
phosphatidyl serine layer of activated
platelet membranes.
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Figure 3. Lipid binding R2163
portion of C1 domain.
Arg 2159 and Arg 2163
residues highlighted.

Hemophilia Severity

R2320

R2215

O-PS
head group

Figure 4. Lipid binding
portion of C2 domain.
Arg 2320 and Arg 2215
residues highlighted and
O-phosphatidyl serine
head group present.
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Data collected from Factor VIII Variant Database

Methods
Site Directed Mutagenesis
Synthesize
Denature double second strand by Digest methylated
stranded plasmid. polymerase chain DNA template
with dpnI enzyme.
Anneal primers.
reaction (PCR).

Transform E. coli with
mutant plasmid to
propagate plasmids.

Isolate DNA and
send off for Sanger
sequencing.

Transform SHuffle B or
K12 E. coli strain with
plasmids containing
proper mutation for
protein expression.

Purification

ELISA
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Figure 6. All proteins were purified by immobilized metal affinity gravity flow
column chromatography with TALON (cobalt affinity) resin. Further
purification achieved with FPLC using a S column. 3

Figure 5. All mutants were created through site directed
mutagenesis and confirmed with Sanger sequencing.2

Figure 7. Binding affinity of mutant
proteins to phosphatidyl serine (PS)
analyzed with an enzyme-linked
immunosorbent assay (ELISA).
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where lipids
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detection
substrate
(Ni-NTA•HRP),
binds His-tag of
protein

Results
C1 Domain Mutations
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hC1 R2159H. Lanes: 1, ladder;
2, nothing; 3, hC1 R2163H post
IMAC elution

1

R2320S

hC1 R2163H. Lanes: 1, ladder; 2, hC1
R2163H post IMAC elution; 3, wash II;
4, wash I; 5, flow through; 6, high
speed supernatant; 7, crude cell lysate

hC2 R2215A. Lanes: 1, hC2 R2215A SHuffle
B post IMAC elution; 2, ladder; 3, hC2
R2215A SHuffle K12 post IMAC elution; 4,
hC2 R2215A SHuffle K12 post IMAC elution

In both cases, the
mutant (R2320T on
right, R2320S on
left), bound PS less
than the WT,
indicating that
residue 2320 does
play a role in platelet
membrane binding.

ELISA: hC2 WT v hC2 R2320S binding to PS.
Reading taken after 1 hour.

R2320T

ELISA: hC2 WT v hC2 R2320T binding to PS.
Reading taken after 2 hours.

Conclusions and Future Work
• C2 Domain: R2320 does play a role in membrane binding.
• Thermodynamic stability and proper folding of human C1 and C2 mutants will be measured with circular dichroism and intrinsic tryptophan fluorescence. Proper folding will
also be confirmed with pull down assays.
• Binding capacity of C1 and C2 mutants for activated platelet surfaces will be measured with enzyme-linked immunosorbent assays (ELISAs) and liposome sedimentation
assays.
• Crystallize the C2 domain mutants to understand conformational changes caused by each mutation and elucidate a working model for membrane binding by the C2 domain.
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